Standard treatment of advanced-stage diffuse large B-cell lymphoma

Semin Hematol. 2006 Oct;43(4):213-20. doi: 10.1053/j.seminhematol.2006.07.004.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma and is not localized in 70% of the cases. Even if the clinical picture, the morphologic aspect, and the prognostic parameters are different from one patient to another, the standard treatment is the same for all patients. Currently, treatment decision is based on the International Prognostic Index (IPI) and age of the patient. Outcome has been completely modified with the introduction of rituximab in combination with chemotherapy. A review of standard treatment and remaining questions is presented.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Humans
  • Lymphoma, B-Cell / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Middle Aged
  • Prednisone / administration & dosage
  • Prognosis
  • Rituximab
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol